Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design

Direct RAS targeting has progressed from pharmacologic proof of concept to routine treatment for selected KRAS G12C-mutant cancers. KRAS G12C inhibitors and KRAS G12C-EGFR combinations established allele- and lineage-specific treatment paradigms. More recently, the multiselective RAS(ON) inhibitor daraxonrasib became t...

A. Hamidi, O. Moaven, R. A. Mahmoudian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.